AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

Jennifer A. Woyach, MD, has been named the new director of the division of hematology at The Ohio State University ...

AstraZeneca chief executive Pascal Soriot ... Imfinzi (durvalumab), PARP inhibitor Lynparza (olaparib), and Calquence (acalabrutinib) for leukaemia. Daiichi Sankyo-partnered HER2 drug Enhertu ...

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...